NCT03170206 2026-02-12
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
17 trialsNCT02185690 2025-08-21
MEK162
University Health Network, Toronto
Phase 1 Completed
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05810740 2024-09-19
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Completed
NCT02613650 2024-08-09
A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers
University of Utah
Phase 1 Completed
NCT01859026 2023-01-19
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02964689 2021-07-14
Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Swiss Cancer Institute
Phase 1 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT03158103 2021-04-30
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01337765 2020-10-09
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT01469130 2020-10-05
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Array BioPharma
Phase 1 Completed
NCT01352273 2020-09-30
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Array BioPharma
Phase 1 Completed
NCT00959127 2020-09-16
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT01649336 2020-09-14
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Array BioPharma
Phase 1 Completed
NCT02041481 2018-01-25
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT01449058 2017-10-02
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
Phase 1 Completed